US2022213121A1PendingUtilityA1

SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY

83
Assignee: SHIONOGI & COPriority: Apr 28, 2005Filed: Jan 27, 2022Published: Jul 7, 2022
Est. expiryApr 28, 2025(expired)· nominal 20-yr term from priority
Inventors:Brian Alvin JohnsTakashi KawasujiTeruhiko TaishiYoshiyuki Taoda
C07D 498/04C07D 498/22A61K 31/551C07D 471/14C07D 471/22A61K 31/4985C07D 498/20C07D 471/04C07D 498/14A61P 37/02A61K 31/519A61P 31/00A61K 9/0053A61P 43/00A61P 31/18A61P 31/12A61K 31/5365A61K 45/06A61K 9/20
83
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.

Claims

exact text as granted — not AI-modified
1 - 56 . (canceled) 
     
     
         57 . A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of a compound of the formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         58 . A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of a compound of the formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         59 . A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of a compound of the formula: 
       
         
           
           
               
               
           
         
       
     
     
         60 . A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of a compound of the formula: 
       
         
           
           
               
               
           
         
       
     
     
         61 . A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound of  claim 57 , or a pharmaceutically acceptable salt thereof. 
     
     
         62 . A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound of  claim 57 . 
     
     
         63 . A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound of  claim 58 , or a pharmaceutically acceptable salt thereof. 
     
     
         64 . A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound of  claim 58 . 
     
     
         65 . A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound of  claim 59 . 
     
     
         66 . A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound of  claim 60 .

Join the waitlist — get patent alerts

Track US2022213121A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.